drugset / Trial / NCT00476853
Efficacy Safety Study Comparing 2 Doses of NVP After Initiating Rifampin-containing TB Therapy
Phase 2
Completed
42 enrolled
The HIV Netherlands Australia Thailand Research Collaboration
Bamrasnaradura Infectious Diseases Institute · collabCentral General Chest Institute · collabChiang Rai Hospital · collabKing Chulalongkorn Memorial Hospital · collabLabor and Welfare · collabThai GPO · collabThai MOPH · collabThe Research Institute of Tuberculosis (RIT), Japan Anti-Tuberculosis Association · collabother sponsors:Japanese MOPH · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
A 48 week, randomized, open-label, two arm study to compare the efficacy, safety and tolerability of HAART containing nevirapine 400 mg/day versus nevirapine 600 mg/day in HIV-1 infected patients started at 2-6 weeks after initiating rifampicin containing antituberculosis therapy.
Timeline
- Start
- 2005-10
- Primary completion
- 2008-09
- Completion
- 2009-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Nevirapine | Small molecule | 400 mg | — |
| Comparator | Nevirapine | Small molecule | 600 mg | — |